Clinical trials: Dyslipidemias
Hypercholesterolemia
Study on the Effect of the Intake of a Calcium-bicarbonate Water on Cholesterol Levels
The goal of this study is to evaluate the hypolipidemic effect (reduction of Low Density Lipoprotein Cholesterol "LDL-C" values) of calcium-bicarbonate mineral water "Lete" (alkaline water, high in bicarbonate and calcium ions…
- Trial name
- NCT07026266
- Testing
- Water
- Where
- Italy
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Società Generale delle Acque Minerali S.p.A.
Dyslipidemia
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
- Trial name
- NCT01301066
- Testing
- Pitavastatin, Pravastatin
- Where
- 35 sites in United States
- Volunteers
- 252 people
- Sponsor
- Kowa Research Institute, Inc.
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Hypercholesterolemia
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
This is a 2-part, Phase 1, placebo-controlled, double-blind, randomized, single and multiple ascending dose study. CAT-2054 will be administered either as an uncoated capsule (CAT-2054) or a coated capsule (CAT-2054-C).
- Trial name
- NCT02374047
- Testing
- CAT-2054, CAT-2054-C, Atorvastatin
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Catabasis Pharmaceuticals
Healthy
A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers
This study is designed to assess any potential interaction between colesevelam and ciclosporin in healthy volunteers.
- Trial name
- NCT00692250
- Testing
- Colesevelam hydrochloride film-coated tablets (Cholestagel)
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Primary Hypercholesterolemia, Mixed Hyperlipidemia
Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
The purpose of this study is to evaluate the effect of SCH 900271 compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 8 weeks of treatment in participants with primary…
- Trial name
- NCT00941603
- Testing
- SCH 900271 15mg, SCH 900271
- Volunteers
- 619 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Dyslipidemia
Caduet in an Untreated Subject Population
The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these…
- Trial name
- CUSP (NCT00332761)
- Testing
- Caduet
- Where
- 34 sites in United States
- Volunteers
- 220 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Hyperlipidemia
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
This trial is a phase III study to evaluate the efficacy , tolerability, and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.
- Trial name
- NCT06780410
- Testing
- Bempedoic Acid Tablet
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Dyslipidemia
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with dyslipidemia when added to an existing statin-modifying therapy.
- Trial name
- NCT01760460
- Testing
- Anacetrapib
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
This was a multicenter, non-randomized, non-interventional three-cohort study with prospective collection of primary data of treatment with newly initiated oral lipid lowering treatment on top of a statin (Oral LLT cohort), newly…
- Trial name
- NCT05362903
- Testing
- Inclisiran
- Where
- 121 sites in Germany
- Volunteers
- 1,868 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components
Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe 10 mg. An open design, randomized, single dose with three periods, six sequences and crossed, in healthy volunteers with fasting…
- Trial name
- NCT04895059
- Testing
- Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose, Rosuvastatin 20mg, Ezetimibe 10mg
- Where
- Mexico
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Hypercholesterolemia
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol
This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol.
- Trial name
- NCT00927459
- Testing
- PRO-040201
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Dyslipidemia
MK0524A Bioequivalence Study (0524A-059)
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.
- Trial name
- NCT00944645
- Testing
- niacin (+) laropiprant (Source 1), Comparator: niacin (+) laropiprant (Source 2)
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
The study will evaluate the use of extended release niacin/laropiprant (ERN/LRPT) combination tablets in a primary prevention population currently not taking or eligible for lipid-modifying therapy (LMT); the population will…
- Trial name
- NCT01414166
- Testing
- ERN/LRPT
- Volunteers
- 244 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia, Dyslipidemia
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the…
- Conditions
- Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
- Trial name
- NCT00267254
- Testing
- torcetrapib/atorvastatin, simvastatin
- Where
- 49 sites in United States
- Volunteers
- 640 people
- Sponsor
- Pfizer
Healthy
A Multiple Dose Study Of PF-06678552 In Healthy Subjects
PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of…
- Trial name
- NCT02079922
- Testing
- PF-06678552
- Where
- Belgium
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.
To determine the effects of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on atorvastatin therapy for at least 4 weeks.
- Trial name
- NCT00754507
- Testing
- colesevelam HCl tablets, and atorvastatin tablets
- Where
- 13 sites in United States
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Homozygous Familial Hypercholesterolemia (HoFH)
A Dose-exploration Study of EDP167 in HoFH
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions.
- Trial name
- NCT07489209
- Testing
- EDP167
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Hypercholesterolemia
The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea
- Trial name
- LAMISIII (NCT04270344)
- Testing
- Pitavastatin 4mg
- Where
- South Korea
- Volunteers
- 905 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Fed
Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions
The purpose of this study single dose bioequivalence of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules with Lotrel® capsules in healthy human subjects and monitor clinical status, adverse events and laboratory…
- Trial name
- NCT01505998
- Testing
- Amlodipine Besylate/Benazepril HCl
- Where
- India
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.